down arrow

Pulse Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74587B1017
USD
13.27
0.28 (2.16%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

13.1613.54

52 Week

12.5625.00
Valuation
Technical
Day's Volume

CASH

178.21 k

Shareholding (Mar 2025)

FII

0.45%

Held by 29 FIIs

DII

95.09%

Held by 5 DIIs

Promoter

0.00%

How big is Pulse Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Pulse Biosciences, Inc. has a market capitalization of $1.01 billion, with net sales of $0.00 million and a net profit of -$60.25 million over the last four quarters. The company reported shareholder's funds of $114.86 million and total assets of $134.06 million as of Dec 24.

Market Cap: As of Jun 18, Pulse Biosciences, Inc. has a market capitalization of 1,011.80 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Pulse Biosciences, Inc. reported net sales of 0.00 million and a net profit of -60.25 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 114.86 million and total assets of 134.06 million.

Read More

What does Pulse Biosciences, Inc. do?

22-Jun-2025

Pulse Biosciences, Inc. is a clinical-stage medical device company specializing in non-thermal electroceutical treatment technology called Nano-Pulse stimulation. As of March 2025, it has a market cap of approximately $1.01 billion and reported a net profit loss of $17 million.

Overview: <BR>Pulse Biosciences, Inc. is a clinical-stage medical device company in the Pharmaceuticals & Biotechnology industry, focusing on a non-thermal electroceutical treatment technology called Nano-Pulse stimulating (NPS).<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,011.80 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -49.26% <BR>Price to Book: 8.54<BR><BR>Contact Details: <BR>Address: 3957 Point Eden Way, HAYWARD CA : 94545-3720 <BR>Tel: 1 510 9064600 <BR>Fax: 1 302 6555049 <BR>Website: http://www.pulsebiosciences.com/

Read More

Who are in the management team of Pulse Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Pulse Biosciences, Inc. includes Mr. Darrin Uecker as CEO and Independent Chairman Mr. Robert Duggan, along with several Independent Directors: Mr. Kenneth Clark, Mr. Mitchell Levinson, Mr. Manmeet Soni, and Dr. Mahkam Zanganeh.

As of March 2022, the management team of Pulse Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Robert Duggan, who serves as the Independent Chairman of the Board.<BR>- Mr. Darrin Uecker, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Kenneth Clark, serving as an Independent Director.<BR>- Mr. Mitchell Levinson, also an Independent Director.<BR>- Mr. Manmeet Soni, who holds the position of Independent Director.<BR>- Dr. Mahkam Zanganeh, serving as an Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, with Mr. Darrin Uecker leading as the CEO.

Read More

Is Pulse Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of March 30, 2023, Pulse Biosciences, Inc. is overvalued at $15.49 due to significant financial distress, reflected in its negative performance metrics and unfavorable comparisons to peers, despite a strong one-year stock return of 44.23%.

As of 30 March 2023, the valuation grade for Pulse Biosciences, Inc. has moved from risky to does not qualify, indicating a significant shift in its financial standing. The company is currently overvalued, particularly given its negative performance metrics. The P/E ratio is not applicable due to the company being loss-making, while the Price to Book Value stands at 9.71, and the EV to EBITDA ratio is at -17.01, highlighting substantial financial distress.<BR><BR>In comparison to its peers, Pulse Biosciences, Inc. shows a less favorable position; for instance, AngioDynamics, Inc. has a P/E of -21.90 and an EV to EBITDA of 373.39, while Alpha Tau Medical Ltd. has a P/E of -7.72 and an EV to EBITDA of -5.48. These ratios suggest that Pulse is not only struggling but also lacks the financial metrics to support its current valuation. Despite a strong one-year stock return of 44.23% compared to the S&P 500's 10.26%, the underlying financial ratios indicate that the stock is not justified at its current price of 15.49.

Read More

Is Pulse Biosciences, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Pulse Biosciences, Inc. shows a mildly bullish technical trend, supported by positive moving averages and Bollinger Bands, despite mixed signals from MACD and KST indicators and underperformance relative to the S&P 500 in the short term.

As of 31 October 2025, the technical trend for Pulse Biosciences, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, and the daily moving averages also reflect a mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend against a mildly bullish monthly trend. <BR><BR>In terms of performance, the stock has underperformed compared to the S&P 500 over the past week, month, and year, but has significantly outperformed over the last three years. Overall, the current technical stance is mildly bullish, driven by the positive signals from the moving averages and Bollinger Bands, despite some bearish indicators on the monthly timeframe.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,012 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

-63.29%

stock-summary
Price to Book

9.68

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-19 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.47%
0%
-11.47%
6 Months
-24.73%
0%
-24.73%
1 Year
-34.57%
0%
-34.57%
2 Years
44.87%
0%
44.87%
3 Years
528.91%
0%
528.91%
4 Years
-26.97%
0%
-26.97%
5 Years
-21.62%
0%
-21.62%

Pulse Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Pulse Biosciences, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Pulse Biosciences, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, and the daily moving averages also reflect a mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend against a mildly bullish monthly trend. In terms of performance, the stock has underperformed compared to the S&P 500 over the past week, month, and year, but has significantly outperformed over the last three years. Overall, the current technical stance is mildly bullish, driven by the positive signals from the moving averages and Bollinger Bands, despite some bearish indicators on the monthly timeframe....

Read More

Is Pulse Biosciences, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Pulse Biosciences, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and KST are mildly bearish, indicating some divergence in strength across time frames. The Bollinger Bands and OBV are both mildly bullish on both weekly and monthly charts, supporting the overall mildly bullish stance. However, the Dow Theory shows a mildly bearish signal on the weekly chart, which tempers the bullish outlook. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, but it has significantly outperformed over the past three years. Overall, the current technical stance is mildly bullish, with key indicators like the weekly MACD and KST driving this view....

Read More

Is Pulse Biosciences, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Pulse Biosciences, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, and the daily moving averages also support a mildly bullish stance. However, the KST shows a bullish weekly signal but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend against a mildly bullish monthly trend. The OBV is mildly bullish in both time frames. In terms of performance, Pulse Biosciences has underperformed the S&P 500 over the past week, month, year-to-date, and year, but has significantly outperformed over the last three years. Overall, the current technical stance is mildly bullish, driven by the positive indicators from moving averages and Bollinger Bands, despit...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-10.62%
EBIT to Interest (avg)
-52.89
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.02%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.71
EV to EBIT
-16.71
EV to EBITDA
-17.01
EV to Capital Employed
1032.51
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-6179.00%
ROE (Latest)
-49.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 21 Schemes (4.46%)

Foreign Institutions

Held by 29 Foreign Institutions (0.45%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -14.29% vs 13.40% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.00",
          "val2": "-17.80",
          "chgp": "-12.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.20",
          "val2": "-16.80",
          "chgp": "-14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.01% vs 27.86% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-53.20",
          "val2": "-42.40",
          "chgp": "-25.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-53.60",
          "val2": "-42.20",
          "chgp": "-27.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-20.00
-17.80
-12.36%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-19.20
-16.80
-14.29%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -14.29% vs 13.40% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-53.20
-42.40
-25.47%
Interest
0.00
1.10
-100.00%
Exceptional Items
-1.90
0.00
Consolidate Net Profit
-53.60
-42.20
-27.01%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -27.01% vs 27.86% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Pulse Biosciences, Inc. stock-summary
stock-summary
Pulse Biosciences, Inc.
Pharmaceuticals & Biotechnology
Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
Company Coordinates stock-summary
Company Details
3957 Point Eden Way , HAYWARD CA : 94545-3720
stock-summary
Tel: 1 510 9064600
stock-summary
http://www.pulsebiosciences.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."